Lexaria Bioscience Corp. (LEXX) has 9 open-market insider trades by 6 insiders since 2023. The most active filer is Richard Christopher, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Richard Christopher | CEO | — | 2 | $250K | 2025-07-29 |
| Christopher Bunka | Dir | — | 1 | $25K | 2026-03-17 |
| Vanessa Carle | Secretary | — | 2 | $11K | 2025-07-29 |
| Catherine C. Turkel | Dir | — | 2 | $9K | 2024-08-12 |
| John Martin Docherty | Pres | — | 1 | $5K | 2025-07-29 |
| William Edward McKechnie | Dir | — | 1 | $5K | 2025-07-29 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Christopher Bunka | Director | Buy | $25K | 2025-07-29 |
| Richard Christopher | CEO | Buy | $14K | 2025-07-29 |
| William Edward McKechnie | Director | Buy | $5K | 2025-07-29 |
| John Martin Docherty | President | Buy | $5K | 2025-07-29 |
| Vanessa Carle | Secretary | Buy | $683 | 2025-07-29 |
| Richard Christopher | CEO | Buy | $236K | 2024-12-02 |
Companies that share insiders with LEXX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Catherine C. Turkel | Director | Buy | $5K | 2024-08-12 |
| Vanessa Carle | Secretary | Sell | $10K | 2024-07-31 |
| Catherine C. Turkel | Director | Buy | $4K | 2023-02-09 |